• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why O2Micro International Is Trading Higher By 7%; Here Are 25 Stocks Moving Premarket

    9/20/22 6:22:02 AM ET
    $ADXN
    $ATHE
    $BCAN
    $CGNX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ADXN alert in real time by email

    Gainers

    • BYND Cannasoft Enterprises Inc. (NASDAQ:BCAN) rose 58.2% to $8.70 in pre-market trading. BYND Cannasoft shares jumped over 32% on Monday after the company announced it has signed a share purchase agreement to acquire 100% ownership of Zigi Carmel Initiatives & Investments for $28 million in stock.
    • Treasure Global Inc. (NASDAQ:TGL) shares rose 14.5% to $2.50 in pre-market trading after declining 13% on Monday.
    • Revelation Biosciences, Inc. (NASDAQ:REVB) rose 11.7% to $0.3797 in pre-market trading after dropping more than 10% on Monday. Revelation Biosciences, last month, posted a Q2 loss of $0.12 per share.
    • Senti Biosciences, Inc. (NASDAQ:SNTI) rose 11.3% to $1.87 in pre-market trading after gaining 5% on Monday.
    • Freight Technologies, Inc. (NASDAQ:FRGT) rose 10.8% to $0.9090 in pre-market trading after declining 9% on Monday.
    • Mega Matrix Corp. (NYSE:MTMT) rose 10.7% to $1.55 in pre-market trading after jumping around 17% on Monday.
    • Mobile Global Esports Inc. (NASDAQ:MGAM) rose 10.3% to $2.67 in pre-market trading after gaining over 4% on Monday.
    • Alterity Therapeutics Limited (NASDAQ:ATHE) rose 9.8% to $0.6149 in pre-market trading.
    • Addex Therapeutics Ltd (NASDAQ:ADXN) rose 7.6% to $0.9201 in pre-market trading after declining around 9% on Monday.
    • O2Micro International Limited (NASDAQ:OIIM) rose 7.1% to $3.17 in pre-market trading after the company announced receipt of a revised preliminary non-binding proposal to acquire the company.
    • Change Healthcare Inc. (NASDAQ:CHNG) rose 6.9% to $27.23 in pre-market trading. A federal judge denied the Justice Department's bid to block UnitedHealth Group from acquiring Change Healthcare.
    • Plains GP Holdings, L.P. (NASDAQ:PAGP) rose 6.1% to $13.15 in pre-market trading.
    • Melco Resorts & Entertainment Limited (NASDAQ:MLCO) rose 5.7% to $6.15 in pre-market trading.
    • Cognex Corporation (NASDAQ:CGNX) rose 5.4% to $43.99 in pre-market trading as the company boosted its guidance for the third quarter ahead of its analyst day, which is scheduled for Tuesday.

     

    Don’t forget to check out our premarket coverage here .

    Losers

    • Virios Therapeutics, Inc. (NASDAQ:VIRI) fell 72.5% to $0.5488 in pre-market trading after the company priced its underwritten public offering of 10.0 million shares of its common stock at $0.50 per share.
    • Pagaya Technologies Ltd. (NASDAQ:PGY) fell 56.6% to $3.03 in pre-market trading after dropping 11% on Monday.
    • AMTD Digital Inc. (NYSE:HKD) fell 9.8% to $83.00 in pre-market trading after dropping around 15% on Monday.
    • Clovis Oncology, Inc. (NASDAQ:CLVS) fell 9.8% to $1.11 in pre-market trading. Clovis Oncology recently submitted applications for Rubraca label expansion in the US and European Union as first-line maintenance treatment in women with advanced ovarian cancer.
    • Valneva SE (NASDAQ:VALN) shares fell 8.6% to $12.29 in pre-market trading after declining around 17% on Monday. Valneva and IDT Biologika will terminate their collaboration following the delivery of inactivated COVID-19 bulk vaccine to Valneva and considering the current order levels and existing inventories.
    • Winc, Inc. (NYSE:WBEV) fell 7.7% to $0.83 in pre-market trading after jumping around 27% on Monday.
    • Seres Therapeutics, Inc. (NASDAQ:MCRB) shares fell 7.7% to $6.07 in pre-market trading. Seres Therapeutics recently announced it completed the rolling submission process for its BLA to the FDA for SER-109 for recurrent C. difficile infection.
    • Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) shares fell 6.3% to $5.70 in pre-market trading after dropping 17% on Monday. Syros announcesd closing of merger with Tyme Technologies and concurrent private placement.
    • Integrated Media Technology Limited (NASDAQ:IMTE) fell 5.8% to $1.80 in pre-market trading after gaining 9% on Monday.
    • Ocugen, Inc. (NASDAQ:OCGN) fell 5.6% to $2.01 in pre-market trading.
    • Ford Motor Company (NYSE:F) fell 4.8% to $14.21 in pre-market trading after the company previewed the effect of parts shortages on the company in the third-quarter and said inflation-related supplier costs during the third quarter will run about $1.0 billion higher than originally expected. The company also projects to have about 40,000 to 45,000 vehicles in inventory at end of third quarter lacking certain parts presently in short supply.
    Get the next $ADXN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADXN
    $ATHE
    $BCAN
    $CGNX

    CompanyDatePrice TargetRatingAnalyst
    Melco Resorts & Entertainment Limited
    $MLCO
    2/17/2026$9.50Neutral → Buy
    UBS
    Cognex Corporation
    $CGNX
    2/17/2026$68.00Hold → Buy
    HSBC Securities
    Plains Group Holdings, L.P.
    $PAGP
    1/28/2026$19.00Neutral → Underperform
    BofA Securities
    Melco Resorts & Entertainment Limited
    $MLCO
    1/16/2026$7.70Overweight → Neutral
    Analyst
    Ford Motor Company
    $F
    1/8/2026$16.00Neutral → Overweight
    Piper Sandler
    Cognex Corporation
    $CGNX
    12/16/2025$50.00Sell → Buy
    Goldman
    Cognex Corporation
    $CGNX
    12/3/2025$35.00Neutral → Underweight
    Analyst
    Senti Biosciences Inc.
    $SNTI
    10/14/2025$12.00Buy
    H.C. Wainwright
    More analyst ratings

    $ADXN
    $ATHE
    $BCAN
    $CGNX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    April 26, 2023 - FDA Approves First Orally Administered Fecal Microbiota Product for the Prevention of Recurrence of Clostridioides difficile Infection

    For Immediate Release: April 26, 2023 Today, the U.S. Food and Drug Administration approved Vowst, the first fecal microbiota product that is taken orally. Vowst is approved for the prevention of recurrence of Clostridioides difficile (C. difficile) infection (CDI) in individuals 18 years of age and older, following antibacterial treatment for recurrent CDI.  “Today’s approval provides patients and healthcare p

    4/26/23 6:04:21 PM ET
    $MCRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for RUBRACA issued to CLOVIS ONCOLOGY INC

    Submission status for CLOVIS ONCOLOGY INC's drug RUBRACA (SUPPL-13) with active ingredient RUCAPARIB CAMSYLATE has changed to 'Approval' on 12/21/2022. Application Category: NDA, Application Number: 209115, Application Classification: Efficacy

    12/22/22 4:37:40 AM ET
    $CLVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for RUBRACA issued to CLOVIS ONCOLOGY INC

    Submission status for CLOVIS ONCOLOGY INC's drug RUBRACA (SUPPL-11) with active ingredient RUCAPARIB CAMSYLATE has changed to 'Approval' on 06/10/2022. Application Category: NDA, Application Number: 209115, Application Classification: Efficacy

    6/13/22 2:20:18 PM ET
    $CLVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADXN
    $ATHE
    $BCAN
    $CGNX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Freight Technologies Completes ISO 9001:2015 Annual Audit

    HOUSTON, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Freight Technologies, Inc. (NASDAQ:FRGT, "Fr8Tech" or the "Company")), a logistics management innovation company offering a diverse portfolio of technology-driven solutions that address distinct challenges within the supply chain ecosystem, is proud to announce it successfully completed its first annual ISO 9001:2015 surveillance audit on December 23, 2025, under the scope of Logistics Services and Transportation of Goods in North America. The confirmation of the internationally recognized certification for both its Mexico and US entities validates the Company's successful implementation of a Quality Management System (QMS) designed to ensure con

    2/20/26 9:00:00 AM ET
    $FRGT
    Professional Services
    Consumer Discretionary

    Senti Bio Participates in Cell & Gene Live Event Highlighting Cutting-Edge Technologies Advancing Cell Therapy Development

    SOUTH SAN FRANCISCO, Calif., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that it participated in a Cell & Gene Live virtual event focused on emerging and enabling technologies designed to advance the development of innovative cell therapies. The Cell & Gene Live webinar, held on February 19, 2026, convened industry leaders and innovators to discuss approaches aimed at improving the design, development and translation of cell therapies. The Company shared perspectives on how its Gene Circuit-based a

    2/20/26 8:50:00 AM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Freight Technologies Announces Two-Year Fleet Rocket Agreement with Marksman

    HOUSTON, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Freight Technologies, Inc. (NASDAQ:FRGT) ("Fr8Tech" or the "Company"), a leading AI-powered logistics technology company, announced today that it has entered into a two-year agreement with Marksman XBF Holding Group SAPI de CV ("Marksman"), a cross-border freight agency, to license Fleet Rocket, the Company's Transportation Management System ("TMS") software platform. Marksman provides cross-border freight agency services supporting shipments between the United States and Mexico with a focus on coordinating international transportation, carrier sourcing, and shipment execution for customers operating in cross-border supply chains. Under the agre

    2/19/26 9:00:00 AM ET
    $FRGT
    Professional Services
    Consumer Discretionary

    $ADXN
    $ATHE
    $BCAN
    $CGNX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Thornton John L bought $99,189 worth of shares (7,520 units at $13.19), increasing direct ownership by 2% to 448,697 units (SEC Form 4)

    4 - FORD MOTOR CO (0000037996) (Issuer)

    11/18/25 4:31:54 PM ET
    $F
    Auto Manufacturing
    Industrials

    Chief Financial Officer Quinby Donald bought $10,400 worth of Ordinary Shares (4,000 units at $2.60) (SEC Form 4)

    4 - Freight Technologies, Inc. (0001687542) (Issuer)

    6/10/25 5:27:05 PM ET
    $FRGT
    Professional Services
    Consumer Discretionary

    Director Fernandes Prabhavathi bought $9,095 worth of shares (10,000 units at $0.91) (SEC Form 4)

    4 - Ocugen, Inc. (0001372299) (Issuer)

    12/2/24 4:15:25 PM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADXN
    $ATHE
    $BCAN
    $CGNX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $ADXN
    $ATHE
    $BCAN
    $CGNX
    SEC Filings

    View All

    Melco Resorts & Entertainment upgraded by UBS with a new price target

    UBS upgraded Melco Resorts & Entertainment from Neutral to Buy and set a new price target of $9.50

    2/17/26 8:04:32 AM ET
    $MLCO
    Hotels/Resorts
    Consumer Discretionary

    Cognex upgraded by HSBC Securities with a new price target

    HSBC Securities upgraded Cognex from Hold to Buy and set a new price target of $68.00

    2/17/26 8:01:33 AM ET
    $CGNX
    Industrial Machinery/Components
    Industrials

    Plains GP downgraded by BofA Securities with a new price target

    BofA Securities downgraded Plains GP from Neutral to Underperform and set a new price target of $19.00

    1/28/26 7:14:10 AM ET
    $PAGP
    Natural Gas Distribution
    Energy

    SEC Form 424B3 filed by Mobile Global Esports Inc.

    424B3 - Mobile Global Esports, Inc. (0001886362) (Filer)

    2/23/26 7:52:02 AM ET
    $MGAM
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    SEC Form EFFECT filed by Mobile Global Esports Inc.

    EFFECT - Mobile Global Esports, Inc. (0001886362) (Filer)

    2/23/26 12:15:12 AM ET
    $MGAM
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    Amendment: Cognex Corporation filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits

    8-K/A - COGNEX CORP (0000851205) (Filer)

    2/19/26 4:06:11 PM ET
    $CGNX
    Industrial Machinery/Components
    Industrials

    $ADXN
    $ATHE
    $BCAN
    $CGNX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Parrotte Dianne M converted options into 8,324 shares, increasing direct ownership by 38% to 30,518 units (SEC Form 4)

    4 - COGNEX CORP (0000851205) (Issuer)

    2/19/26 5:02:11 PM ET
    $CGNX
    Industrial Machinery/Components
    Industrials

    CEO & President Moschner Matthew converted options into 5,085 shares and covered exercise/tax liability with 1,600 shares, increasing direct ownership by 42% to 11,847 units (SEC Form 4)

    4 - COGNEX CORP (0000851205) (Issuer)

    2/19/26 4:59:29 PM ET
    $CGNX
    Industrial Machinery/Components
    Industrials

    SVP, Chief Financial Officer Fehr Dennis converted options into 5,085 shares and covered exercise/tax liability with 1,618 shares, increasing direct ownership by 38% to 12,578 units (SEC Form 4)

    4 - COGNEX CORP (0000851205) (Issuer)

    2/19/26 4:56:26 PM ET
    $CGNX
    Industrial Machinery/Components
    Industrials

    $ADXN
    $ATHE
    $BCAN
    $CGNX
    Leadership Updates

    Live Leadership Updates

    View All

    Cognex Appoints Sami Atiya and Chris Donato to Board of Directors

    NATICK, Mass., Feb. 17, 2026 /PRNewswire/ -- Cognex Corporation (NASDAQ:CGNX), ("Cognex"), the global technology leader in industrial machine vision, today announced the appointments of Dr. Sami Atiya and Mr. Chris Donato to Cognex's Board of Directors (the "Board"), effective March 2, 2026.  "We are excited to welcome Sami and Chris to our Board," said Matt Moschner, President and CEO. "We remain focused on our strategic objectives of becoming the leading provider of AI technology for industrial machine vision, delivering the best customer experience in our industry and doublin

    2/17/26 8:00:00 AM ET
    $CGNX
    Industrial Machinery/Components
    Industrials

    Seres Provides Program and Corporate Updates and Prioritizes Emerging Programs in Inflammatory & Immune Diseases

    Seres has finalized the protocol for the Phase 2 study of SER-155 in patients undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) with the FDA and has advanced key study startup activities and will pause further investment, while efforts to seek funding for the study remain ongoing Company's runway extension actions, including reducing the workforce by approximately 30%, are expected to extend its cash runway through Q3 2026 Seres will focus on advancing development of its early-stage live biotherapeutic programs in Inflammatory and immune diseases and supporting the read-out of clinical results from the fully enrolled Investigator-sponsored SER-155 study in immune checkp

    2/12/26 7:00:00 AM ET
    $MCRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ocugen Appoints Rita Johnson-Greene to Chief Financial Officer

    MALVERN, Pa., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the appointment of Rita Johnson-Greene as Chief Financial Officer (CFO). "Mrs. Johnson-Greene's diverse background across a variety of strategic roles at organizations representing many facets of the industry make her well-suited to serve as Ocugen's CFO," said Dr. Shankar Musunuri, Chairman, CEO, and Co-founder of Ocugen. "We look forward to her leadership as we enter into a transformative time at Ocugen, beginning with the submission of the first of three Biologics License Applications (BLAs) this

    2/9/26 7:02:00 AM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADXN
    $ATHE
    $BCAN
    $CGNX
    Financials

    Live finance-specific insights

    View All

    Senti Bio Participates in Cell & Gene Live Event Highlighting Cutting-Edge Technologies Advancing Cell Therapy Development

    SOUTH SAN FRANCISCO, Calif., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that it participated in a Cell & Gene Live virtual event focused on emerging and enabling technologies designed to advance the development of innovative cell therapies. The Cell & Gene Live webinar, held on February 19, 2026, convened industry leaders and innovators to discuss approaches aimed at improving the design, development and translation of cell therapies. The Company shared perspectives on how its Gene Circuit-based a

    2/20/26 8:50:00 AM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Ocugen to Host Conference Call on Wednesday, March 4, 2026 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2025 Financial Results

    MALVERN, Pa., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it will host a conference call and live webcast to discuss the Company's fourth quarter and full year 2025 financial results and provide a business update at 8:30 a.m. ET on Wednesday, March 4, 2026. Ocugen will issue a pre-market earnings announcement on the same day. Attendees are invited to participate on the call using the following details: Dial-in Numbers: (800) 715-9871 for U.S. callers and (646) 307-1963 for international callersConference ID: 3029428Webcast: Available on the events sec

    2/18/26 7:02:00 AM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Melco Resorts Announces Unaudited Fourth Quarter 2025 Earnings

    MACAU, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Melco Resorts & Entertainment Limited (NASDAQ:MLCO) ("Melco Resorts" or the "Company"), a developer, owner, and operator of integrated resort facilities in Asia and Europe, today reported its unaudited financial results for the fourth quarter and full year ended December 31, 2025. Total operating revenues for the fourth quarter of 2025 were US$1.29 billion, representing an increase of approximately 9% from US$1.19 billion for the comparable period in 2024. The increase in total operating revenues was primarily attributable to the improved overall rolling chip and mass market table games performance. Operating income for the fourth quarter of 2025

    2/12/26 7:56:47 AM ET
    $MLCO
    Hotels/Resorts
    Consumer Discretionary

    $ADXN
    $ATHE
    $BCAN
    $CGNX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Senti Biosciences Inc.

    SC 13D/A - Senti Biosciences, Inc. (0001854270) (Subject)

    12/4/24 7:08:03 PM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by AMTD Digital Inc.

    SC 13G/A - AMTD Digital Inc. (0001809691) (Subject)

    11/14/24 9:33:22 PM ET
    $HKD
    Finance: Consumer Services
    Finance

    Amendment: SEC Form SC 13G/A filed by Syros Pharmaceuticals Inc.

    SC 13G/A - Syros Pharmaceuticals, Inc. (0001556263) (Subject)

    11/14/24 5:28:08 PM ET
    $SYRS
    Biotechnology: Pharmaceutical Preparations
    Health Care